Quarterly ResultMay 14, 2026, 07:11 AM
Pelthos Therapeutics Q1 Revenue $10.7M, Net Loss $(10.2)M
AI Summary
Pelthos Therapeutics announced its first quarter 2026 financial results, reporting ZELSUVMI net product revenue of $10.7 million, a 17% increase quarter-over-quarter. The company also saw a 25% rise in ZELSUVMI units dispensed and expanded its sales force. Net loss significantly improved to $(10.2) million from $(21.7) million in the previous quarter, partly due to a gain from the change in fair value of convertible debt. Pelthos highlighted its $32.0 million cash balance and plans for future product launches.
Key Highlights
- ZELSUVMI net product revenue grew 17% quarter-over-quarter to $10.7 million.
- ZELSUVMI units dispensed increased 25% quarter-over-quarter to 7,884 units.
- Net loss significantly improved to $(10.2) million from $(21.7) million in Q4 2025.
- Secured a $50.0 million senior secured term loan facility, drawing $30.0 million.
- Cash balance stood at $32.0 million as of March 31, 2026.
- Selling, general and administrative expenses rose 14% quarter-over-quarter to $21.1 million.
- Anticipates launching XEPI® in early 2027 and XEGLYZE® in mid-2027.